H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
MoonLake Analyst Ratings
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $65
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $55 to $100
MoonLake Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Hidradenitis Suppurativa Treatment Prospects
MoonLake Immunotherap Price Target Maintained With a $62.00/Share by Needham
Barclays Sticks to Their Hold Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Analyst Ratings
Wolfe Research Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating
Barclays Keeps Their Hold Rating on MoonLake Immunotherapeutics (MLTX)
Needham Maintains Buy on MoonLake, Lowers Price Target to $62
MoonLake Immunotherapeutics (MLTX) Receives a Buy From TD Cowen
MoonLake Analyst Ratings